阿立哌唑治疗抽动障碍的应用进展

doi:10.3969/j.issn.1004-583X.2024.09.019

摘要/Abstract

摘要：

抽动障碍是儿童常见神经发育疾病之一,发病机制与脑内多巴胺活动过度、受体超敏等有关。阿立哌唑是治疗儿童抽动障碍(tic disorder, TD)的一线药物,但存在超说明书用药、治疗剂量不规范等问题,且药动学个体差异明显。为提高阿立哌唑治疗儿童TD的临床效果及安全性,减少不良反应,本文就目前国内外阿立哌唑治疗TD的作用机制、药动学特点、用药现状进行总结。

关键词: 抽搐性运动障碍, 阿立哌唑, 药动学, 不良反应

中图分类号:

R741.041

李静, 郑华城, 吕静静. 阿立哌唑治疗抽动障碍的应用进展[J]. 临床荟萃, 2024, 39(9): 861-864.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.09.019

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I9/861

参考文献 37

[1]	Furlong Y, Koonamave RL, Sarich E, et al. Refractory case of Tourette's syndrome treated successfully with comprehensive behavioural therapy and aripiprazole[J]. J Paediatr Child Health, 2022, 58(3):539-541.
[2]	Zilhão NR, Padmanabhuni SS, Pagliaroli L, et al. Epigenome-wide association study of tic disorders[J]. Twin Res Hum Genet, 2015, 18:1-11.
[3]	Mohr P, Masopust J, Kopeček M. Dopamine Receptor Partial Agonists:Do they differ in their clinical efficacy?[J]. Front Psychiatry, 2022, 12:781946.
[4]	Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors[J]. J Pharmacol Exp Ther, 2002, 302:381-389. doi: 10.1124/jpet.102.033175 pmid: 12065741
[5]	Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor[J]. Eur J Pharmacol, 2022, 441(3):137-140.
[6]	Carlsson A. Dopamine receptor agonists: Intrinsic activity vs. state of receptor[J]. J Neural Transm, 1983, (57):309-315.
[7]	Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome-New therapeutic option[J]. Neurol Neurochir Pol, 2018, 52:84-87.
[8]	Lamothe H, Schreiweis C, Mondragón-González LS, et al. The Sapap3-/- mouse reconsidered as a comorbid model expressing a spectrum of pathological repetitive behaviours[J]. Transl Psychiatry, 2023, 13(1):26.
[9]	辛莹莹, 石亮, 梅艳. 阿立哌唑治疗抽动障碍的药动学研究进展[J]. 药物流行病学杂志, 2023, 32(2):221-224.
[10]	Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia[J]. Ther Drug Monit, 2008, 30: 462-466. doi: 10.1097/FTD.0b013e318178e18d pmid: 18641558
[11]	Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome-new therapeutic option[J]. Neurol Neurochir Pol, 2018, 52(1):84-87.
[12]	Kirschbaum KM, Müller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects[J]. World J Biol Psychiatry, 2008, 9(3):212-218.
[13]	Xin Y, Gao L, Tuo Y, et al. Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes[J]. Front Pharmacol, 2022;13:1048498.
[14]	Seideman MF, Seideman TA. A review of the current treatment of to-urette syndrome[J]. J Pediatr Pharmacol Ther, 2020, 25(5):401-412. doi: 10.5863/1551-6776-25.5.401 pmid: 32641910
[15]	Pozzi M, Pisano S, Bertella S, et al. Persistence in therapy with risperidone and aripiprazole in pediatric outpatients: A 2-year naturalistic comparison[J]. J Clin Psychiatry, 2016, 77(12):1601-1609. doi: 10.4088/JCP.15m10247 pmid: 27780333
[16]	Coustals N, Ménard ML, Cohen D. Aripiprazole in children and adolescents[J]. J Child Adolesc Psychopharmacol, 2021, 31(1):4-32.
[17]	Chevreuil C, Polard E, Lemonnier E, et al. Aripiprazole use in children and adolescent psychiatric patients[J]. Therapie, 2011, 66 (2): 123-130. pmid: 21635859
[18]	Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder[J]. J Clin Psychiatry, 2013(74):e772-780.
[19]	Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourettesyndrome and chronic tic disorders[J]. Neurology, 2019, 92(19):907-915. doi: 10.1212/WNL.0000000000007467 pmid: 31061209
[20]	Jakobsen KD, Bruhn CH, Pagsberg AK, et al. Neurological, metabolic, and psychiatric adverse events in children and adolescents treated with aripiprazole[J]. J Clin Psychopharmacol, 2016, 36:496-499. doi: 10.1097/JCP.0000000000000548 pmid: 27504593
[21]	Liu Y, Hong N, Wang C, et al. Effectiveness and tolerability of aripiprazole in childrenand adolescents with Tourette’s disorder: A meta-analysis[J]. J Child Adol Psychop, 2015, 26(5):436-441.
[22]	Wichniak A, Samochowiec J, Szulc A, et al. The position statement of the working group of the polish psychiatric association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders[J]. Psychiatr Pol, 2021, 55(5):941-966. doi: 10.12740/PP/138177 pmid: 34997736
[23]	Rasmussen L, Bilenberg N, Thrane JM, et al. Use of tic-suppressing medication and other psychotropic drugs in children and adolescents with newly diagnosed tic disorders in Denmark[J]. J Child Adolesc Psychopharmacol, 2020, 30(8):476-485.
[24]	Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part Ⅲ: Pharmacological treatment[J]. Eur Child Adolesc Psychiatry, 2022, 31(3):425-441.
[25]	Cox JH, Cavanna AE. Aripiprazole for the treatment of Tourette syndrome[J]. Expert Rev Neurother, 2021, 21(4):381-391. doi: 10.1080/14737175.2021.1893693 pmid: 33612035
[26]	Besag FM, Vasey MJ, Lao KS, et al. Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review[J]. J Psychopharmacol, 2021, 35(9):1037-1061.
[27]	Hamamoto Y, Fujio M, Nonaka M, et al. Expert consensus on pharmacotherapy for tic disorders in Japan[J]. Brain Dev, 2019, 41(6):501-506.
[28]	Farhat LC, Behling E, Landeros-Weisenberger A, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: A systematic review and network meta-analysis[J]. Lancet Child Adolesc Health, 2023, 7(2):112-126.
[29]	Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome[J]. Int J Neuropsychopharmacol, 2005, 8(3):489-490.
[30]	Rothenberger A, Roessner V. Psychopharmacotherapy of obsessive compulsive symptoms within the framework of Tourette Syndrome[J]. Curr Neuropharmacol, 2019, 17(8):703-709. doi: 10.2174/1570159X16666180828095131 pmid: 30152283
[31]	Tsai LH, Lin JW, Lee MC. Social communication disorder in an adolescent with ADHD and Tourette's Disorder treated with aripiprazole[J]. Psychiatr Danub, 2022, 34(1):96-99. doi: 10.24869/psyd.2022.96 pmid: 35467619
[32]	Masi G, Pfanner CH, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: A naturalistic comparative study[J]. J Psychiatr Res, 2013, 47(8):1007-1012. doi: 10.1016/j.jpsychires.2013.04.003 pmid: 23664673
[33]	Soltanifar A, Lashkarnevis R, Ziaee M, et al. Investigating the effects and side effects of two antipsychotic drugs in the treatment of children and adolescents with Tourette Syndrome: A semi-experimental research[J]. Curr Drug Discov Technol, 2023, 20(6):1-8. doi: 10.2174/1570163820666230609095720 pmid: 37303178
[34]	张红, 黄海忠, 林国栋. 利培酮与阿立哌唑治疗儿童抽动障碍的随机对照研究[J]. 临床荟萃, 2015, 30(12):1393-1396.
[35]	王鑫, 徐冲锋, 张敏. 阿立哌唑与氟哌啶醇治疗儿童抽动障碍疗效的Meta分析[J]. 中国社区医师, 2018, 34(34):72-75.
[36]	李丹. 阿立哌唑治疗儿童抽动障碍的疗效观察[J]. 中国冶金工业医学杂志, 2024, 41(1):110-111.
[37]	Rizwan M, Shahid NUA, Naguit N, et al. Efficacy of behavioural intervention, antipsychotics, and alpha agonists in the treatment of tics disorder in Tourette's Syndrome[J]. Cureus, 2022, 14(2):e22449.

阿立哌唑治疗抽动障碍的应用进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杜佳宜, 刘丽丽, 何永忠, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病化疗期间严重不良事件临床观察[J]. 临床荟萃, 2023, 38(2): 149-154.
[2]	陈珺. 钠-葡萄糖转运蛋白2抑制剂在2型糖尿病患者中用药安全性的研究进展[J]. 临床荟萃, 2023, 38(11): 1042-1047.
[3]	吕静静, 李静, 郑华城. 儿童抽动障碍与精神心理及环境因素的研究进展[J]. 临床荟萃, 2023, 38(11): 1031-1033.
[4]	李平, 徐曼华, 何兰英, 王立峰, 张培, 宋丽华. 阿立哌唑和奥氮平治疗老年痴呆叠加不同亚型谵妄的对照研究[J]. 临床荟萃, 2022, 37(8): 699-703.
[5]	冯雄彩, 霍丽娟. 含呋喃唑酮四联方案根除幽门螺杆菌引发严重不良反应1例[J]. 临床荟萃, 2022, 37(6): 548-550.
[6]	黄业鸿, 刘改芳, 忻晨曦, 赵云红, 吴婧. 质子泵抑制剂大剂量二联与铋剂四联在幽门螺杆菌根除治疗中的疗效比较[J]. 临床荟萃, 2022, 37(3): 230-233.
[7]	黄佳圆, 潘半舟, 纪红, 梅静峰, 范朝晖, 周云. 帕博利珠单抗致剥脱性皮炎1例的临床诊治并同期应用帕博利珠单抗44例皮肤毒性分析[J]. 临床荟萃, 2022, 37(2): 150-154.
[8]	陈礼龙, 刘务朝, 司秋艳, 张建平, 程荣, 吴权. 不同剂量硫酸氢氯吡格雷对脑梗死患者血流动力学指标及血清miR-191、miR-18a水平的影响[J]. 临床荟萃, 2021, 36(7): 608-611.
[9]	卢昊阳, 卢家忠, 韩明锋, 吕新才, 张标, 戎成振, 贾蕾蕾, 潘强强, 马蕾蕾, 赵韧. 新型冠状病毒肺炎合并心血管疾病的临床治疗观察[J]. 临床荟萃, 2021, 36(3): 203-207.
[10]	林晓霞, 柯钟灵, 陈燕惠, 陈慧, 陈先睿. 维生素D水平与抽动障碍关系的meta分析[J]. 临床荟萃, 2020, 35(12): 1061-1066.
[11]	孙振晓，于相芬. 多奈哌齐的不良反应[J]. 临床荟萃, 2020, 35(1): 80-83.
[12]	王文媛. 嵌合抗原受体T细胞免疫治疗不良反应的研究进展[J]. 临床荟萃, 2019, 34(11): 1038-1041.
[13]	李雅莉;刘煜. 氟哌啶醇治疗儿童抽动症致亚急性视力下降1例并文献复习[J]. 临床荟萃, 2015, 30(9): 1059-1060.
[14]	张红;黄海忠;林国栋. 利培酮与阿立哌唑治疗儿童抽动障碍的随机对照研究[J]. 临床荟萃, 2015, 30(12): 1393-1396.
[15]	康伟格;杨宝刚. 成人慢性多发性抽动症1例治疗经验[J]. 临床荟萃, 2013, 28(8): 924-925.